Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2007 3
2008 1
2010 2
2012 1
2014 1
2016 2
2017 1
2020 1
2021 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Exploiting Preexisting Immunity to Enhance Oncolytic Cancer Immunotherapy.
Tähtinen S, Feola S, Capasso C, Laustio N, Groeneveldt C, Ylösmäki EO, Ylösmäki L, Martins B, Fusciello M, Medeot M, Tagliamonte M, Chiaro J, Hamdan F, Peltonen K, Ranki T, Buonaguro L, Cerullo V. Tähtinen S, et al. Among authors: ranki t. Cancer Res. 2020 Jun 15;80(12):2575-2585. doi: 10.1158/0008-5472.CAN-19-2062. Epub 2020 Feb 27. Cancer Res. 2020. PMID: 32107211
Retrospective, Registry-based, Cohort Investigation of Clinical Outcomes in Patients with Cutaneous Squamous Cell Carcinoma and Basal Cell Carcinoma in Finland.
Tuominen S, Ukkola-Vuoti L, Riihilä P, Knuutila JS, Kähäri VM, Lassenius M, Ranki T, Pousar K, Vassilev L, Vuoti S, Mattila K. Tuominen S, et al. Among authors: ranki t. Acta Derm Venereol. 2022 Apr 8;102:adv00693. doi: 10.2340/actadv.v102.2073. Acta Derm Venereol. 2022. PMID: 35356995 Free PMC article.
Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform.
Ylösmäki E, Ylösmäki L, Fusciello M, Martins B, Ahokas P, Cojoc H, Uoti A, Feola S, Kreutzman A, Ranki T, Karbach J, Viitala T, Priha P, Jäger E, Pesonen S, Cerullo V. Ylösmäki E, et al. Among authors: ranki t. Mol Ther Oncolytics. 2021 Feb 10;20:459-469. doi: 10.1016/j.omto.2021.02.006. eCollection 2021 Mar 26. Mol Ther Oncolytics. 2021. PMID: 33718594 Free PMC article.
Tissue-specific promoters active in CD44+CD24-/low breast cancer cells.
Bauerschmitz GJ, Ranki T, Kangasniemi L, Ribacka C, Eriksson M, Porten M, Herrmann I, Ristimäki A, Virkkunen P, Tarkkanen M, Hakkarainen T, Kanerva A, Rein D, Pesonen S, Hemminki A. Bauerschmitz GJ, et al. Among authors: ranki t. Cancer Res. 2008 Jul 15;68(14):5533-9. doi: 10.1158/0008-5472.CAN-07-5288. Cancer Res. 2008. PMID: 18632604
Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.
Koski A, Kangasniemi L, Escutenaire S, Pesonen S, Cerullo V, Diaconu I, Nokisalmi P, Raki M, Rajecki M, Guse K, Ranki T, Oksanen M, Holm SL, Haavisto E, Karioja-Kallio A, Laasonen L, Partanen K, Ugolini M, Helminen A, Karli E, Hannuksela P, Pesonen S, Joensuu T, Kanerva A, Hemminki A. Koski A, et al. Among authors: ranki t. Mol Ther. 2010 Oct;18(10):1874-84. doi: 10.1038/mt.2010.161. Epub 2010 Jul 27. Mol Ther. 2010. PMID: 20664527 Free PMC article. Clinical Trial.
Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 - Support for clinical studies on advanced cancer treatment.
Kuryk L, Vassilev L, Ranki T, Hemminki A, Karioja-Kallio A, Levälampi O, Vuolanto A, Cerullo V, Pesonen S. Kuryk L, et al. Among authors: ranki t. PLoS One. 2017 Aug 10;12(8):e0182715. doi: 10.1371/journal.pone.0182715. eCollection 2017. PLoS One. 2017. PMID: 28796812 Free PMC article.
17 results